The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation
Open accessAbstract
Iron deficiency (ID) is usually treated with oral iron salts, but up to 50% of patients complain of gastrointestinal side effects, leading to reduced compliance with treatment. Intravenous (IV) iron formulations are increasingly safe, but there is still a risk of infusion, hypersensitivity reactions and the need for venous access and infusion monitoring. Sucrosomial® Iron (SI) is an innovative oral iron formulation in which ferric pyrophosphate is protected by a phospholipid bilayer plus a sucrester matrix (sucrosome), which is absorbed through para-cellular and trans-cellular routes (M cells). This confers SI’s unique structural, physicochemical and pharmacokinetic characteristics, together with its high iron bioavailability and excellent gastrointestinal tolerance. The analysis of the available evidence supports oral SI iron as a valid option for ID treatment, which is more efficacious and tolerable than oral iron salts. SI has also demonstrated a similar effectiveness, with lower risks, in patients usually receiving IV iron (e.g., chronic kidney disease, cancer, bariatric surgery). Thus, oral SI emerges as a valuable first option for treating ID, especially for subjects with intolerance to iron salts or those for whom iron salts are inefficacious. Moreover, SI should also be considered as an alternative to IV iron for initial and/or maintenance treatment in different patient populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Prevalence of iron deficiency across pathologies. (Data taken from references [5,6,7,8,9,10,11,12,13]).](https://figures.cochat.ai/paper-figures/9feb25a1d42c49aca53a32d1f6c2c214/sucrosomial-iron-a-new-generation-iron-for-improving-oral-supplementation-figure-1.jpg)


![Figure 4 Gastro-resistance and intestinal absorption of Sucrosomial® iron. (A) Gastro-resistant properties of Sucrosomial® iron compared to a sucrester-free iron preparation in an in-vitro simulated gastric fluid digestion at pH 1.2. (B) The involvement of M cells in Sucrosomial® iron uptake was evaluated using an in vitro CACO2/RajiB co-culture. The iron to protein ratio was significantly increased in co-culture cells treated with Sucrosomial® iron (SI), compared to other oral iron formulations: ferrous sulfate (FS), ferrous ascorbate (FeASC), ferrous ethylene-diamine-tetra-acetate (FeEDTA), ferrous bisglycinate (FeBIS), and control (no iron) (data are mean ± SEM, * p < 0.05) (Adapted from references [41,42]).](https://figures.cochat.ai/paper-figures/83fa6be5e09541909c5e01b4a5810dae/sucrosomial-iron-a-new-generation-iron-for-improving-oral-supplementation-figure-4.jpg)
![Figure 5 Bioavailability experiments on CACO-2 cells. Ferritin expression by cells treated with Sucrosomial® iron (SI) was significantly increased, compared to cells treated with ferrous sulfate (FS), phospholipid containing ferric pyrophosphate (Lipofer®), or micronized, dispersible ferric pyrophosphate (SunActive®) (A) or different iron salts, FS, ferric pyrophosphate (FePYR), ferrous ascorbate (FeASC), ferrous ethylene-diamine-tetra-acetate (FeEDTA), ferrous bisglycinate (FeBIS), and control (no iron) (B) (Data are mean ± SEM, * p < 0.001 SI vs. other iron compounds) (Adapted from references [41,45]).](https://figures.cochat.ai/paper-figures/90057c5c3069409ba253d8732f1c9c9f/sucrosomial-iron-a-new-generation-iron-for-improving-oral-supplementation-figure-5.jpg)
![Figure 6 Iron supplementation in anemic piglets and mice. (A) Hemoglobin concentration in anemic piglets treated with iron dextran (FeDEX) or Sucrosomial® iron (SI) (Data are mean ± SD; * p < 0.001, treatment vs. anemic; ** p < 0.001, SI vs. FeDEX). (B) Change in hemoglobin levels in anemic mice after a 14-day treatment with Sucrosomial® iron (SI) or ferrous sulfate (FS). (Data are mean ± SD; * p < 0.01, SI or FS vs. saline; ** p < 0.05, FS vs. vehicle) (Adapted from references [46,47]).](https://figures.cochat.ai/paper-figures/5c74524764144e00aff389f257b54e0b/sucrosomial-iron-a-new-generation-iron-for-improving-oral-supplementation-figure-6.jpg)
![Figure 7 Comparative efficacy of different oral iron formulations for treating bleeding-induced moderate-to-severe anemia. SunActive®, micronized ferric pyrophosphate. Each oral iron formulation was tested in 60 patients (Data taken from reference [89]).](https://figures.cochat.ai/paper-figures/9eb6a9b1ed3d4d498f2347d5433eb672/sucrosomial-iron-a-new-generation-iron-for-improving-oral-supplementation-figure-7.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Pre-clinical data indicate that it may be more tolerable than other oral iron formulations whilst having similar effectiveness at restoring iron levels [32].”
From Oral Iron Supplementation—Gastrointestinal Side Effects and the Impact on the Gut Microbiota (2021) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
A systematic analysis of global anemia burden from 1990 to 2010
Kassebaum, N. J., Jasrasaria, R., Naghavi, M., Wulf, S. K., Johns, N., Lozano, R., Regan, M., Weatherall, D., Chou, D. P., Eisele, T. P., et al. (2014) · Blood · doi:10.1182/blood-2013-06-508325 · Cited by 2,075
ACG Clinical Guidelines: Diagnosis and Management of Celiac Disease
Rubio-Tapia, A., Hill, I. D., Kelly, C. P., Calderwood, A. H., & Murray, J. A. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.79 · Cited by 1,681
Camaschella, C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1401038 · Cited by 1,678 · cited 3×
“In turn, hepcidin binds ferroportin, especially at the enterocytes, promoting its internalization and degradation, thus preventing iron absorption, while iron recirculation from macrophages seems to be less affected [4,14,55].”
BackgroundHepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation
Ganz, T. (2003) · Blood · doi:10.1182/blood-2003-03-0672 · Cited by 1,544 · cited 2×
“In turn, hepcidin binds ferroportin, especially at the enterocytes, promoting its internalization and degradation, thus preventing iron absorption, while iron recirculation from macrophages seems to be less affected [4,14,55].”
BackgroundClinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage
Carson, J. L., Guyatt, G., Heddle, N. M., Grossman, B. J., Cohn, C. S., Fung, M. K., Gernsheimer, T., Holcomb, J. B., Kaplan, L. J., Katz, L. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.9185 · Cited by 1,113
International consensus statement on the peri‐operative management of anaemia and iron deficiency
Muñoz, M., Acheson, A. G., Auerbach, M., Besser, M., Habler, O., Kehlet, H., Liumbruno, G. M., Lasocki, S., Meybohm, P., Rao Baikady, R., et al. (2017) · Anaesthesia · doi:10.1111/anae.13773 · Cited by 876
Self-citation
Research works printed but not linked: 12
- 2017, Anaemia in the elderly, Med. Clin., 149, 496
- Starzynski, 2017, Comparison of the therapeutical potential of oral Sucrosomial® iron and parenteral iron dextran supplementations in neonatal iron deficiency anemia in pigs, Am. J. Hematol., 92, E286
- Brilli, E., Barnadas, R., Camacho, M., Giordano, G., and Tarantino, G. (2018, January 8–11). Sucrosomial® Iron Absorption Involves M Cells Interaction. Proceedings of the European Iron Club Annual Meeting, Zürich, Switzerland.
- Berardi, 2016, Efficacy of oral Sucrosomial® iron in puerperium anemia, Exp. Rev. Hematol., 9, 40
- Barni, 2017, Upfront use of Sucrosomial® iron prevents transfusions in cancer patients on chemotherapy, Support. Care Cancer, 25, S144
- Bastida, 2016, Efficacy and tolerability of Sucrosomial iron supplementation in IBD patients with iron deficiency anemia and intolerance to iron oral salts, Exp. Rev. Hematol., 9, 6
- Stuklov, N.I., Basiladze, I.G., Pivnik, A.V., Knyazev, O.V., and Parfenov, A.I. (2018). Characteristics and modern treatment of iron deficiency syndromes in inflammatory bowel diseases. Exp. Rev. Hematol., 10, in press.
- Farinati, F., and Maddalo, G. (2018). Iron and/or B12 deficient anemia in autoimmune gastritis. High dose sucrosomial iron supplementation: Preliminary data of a single center experience. Exp. Rev. Hematol., 10, in press.
- Shipton, 2018, Deficiencies of vitamin B12, folate and iron over 4 years of follow-up post-bariatric surgery [abstract], Br. J. Surg., 105, 28
- Karavidas, A., Trogkanis, E., Farmakis, D., Papingiotis, G., Matzaraki, V., Perpinia, A., and Parissis, J. (2018). Oral sucrosomial iron improves quality of life in heart failure patients with iron deficiency: A preliminary proof-of-concept study. Exp. Rev. Hematol., 10, in press.
- Cabrera, P., Gómez, S., Herrero, V., Martín, E., Pavía, J., and Muñoz, M. (2016, January 2–3). Prevalence and consequences of anaemia among patients hospitalised at the internal medicine ward: A single centre audit. Proceedings of the 15th European Congress of Internal Medicine, Amsterdam, The Netherlands.
- Giordano, 2016, Reduction of inflammatory markers with liposomal iron (Sideral®). Pre-clinical and clinical results, Exp. Rev. Hematol., 9, S17
Cited by
Pasricha, S.-R., Tye-Din, J., Muckenthaler, M. U., & Swinkels, D. W. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32594-0 · Cited by 1,069
Iron deficiency anaemia: pathophysiology, assessment, practical management
Kumar, A., Sharma, E., Marley, A., Samaan, M. A., & Brookes, M. J. (2022) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2021-000759 · Cited by 344
Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment
Batchelor, E. K., Kapitsinou, P., Pergola, P. E., Kovesdy, C. P., & Jalal, D. I. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019020213 · Cited by 334
Mechanism and Intervention Measures of Iron Side Effects on the Intestine
Qi, X., Zhang, Y., Guo, H., Hai, Y., Luo, Y., & Yue, T. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2019.1630599 · Cited by 142
Oral Iron Supplementation—Gastrointestinal Side Effects and the Impact on the Gut Microbiota
Bloor, S. R., Schutte, R., & Hobson, A. R. (2021) · Microbiology Research · doi:10.3390/microbiolres12020033 · Cited by 117
“Pre-clinical data indicate that it may be more tolerable than other oral iron formulations whilst having similar effectiveness at restoring iron levels [32].”
Background
Metadata
- Authors
- Gómez-Ramírez, S., Brilli, E., Tarantino, G., & Muñoz, M.
- Affiliations
- Department of Internal Medicine, University Hospital Virgen de la Victoria. Campus de Teatinos, 2010 Málaga, Spain
- Scientific Department, Alesco S.r.l. Via delle Lenze, 216/B, 56122 Pisa, Italy
- PharmaNutra SpA (Italy) (IT)
- Perioperative Transfusion Medicine, Department of Surgical Specialties, Biochemistry and Immunology, School of Medicine, Campus de Teatinos, 29071 Málaga, Spain
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2018-10-04
- Volume
- 11
- Issue
- 4
- Pages
- 97
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC6316120
- OpenAlex
- W2895639972
- Cited by
- 132
- References
- 81
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 28 · 2023: 19 · 2022: 14 · 2021: 20 · 2020: 17 · 2019: 7 · 2018: 1
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Keywords
- sucrosomial iron, oral iron supplementation, iron deficiency, ferric pyrophosphate, phospholipid bilayers, M cells, iron bioavailability, gastrointestinal tolerance, chronic kidney disease, cancer patients, bariatric surgery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation. https://app.cochat.ai/papers/10.3390/ph11040097
- The paper
- Gómez-Ramírez, S., Brilli, E., Tarantino, G., & Muñoz, M. (2018). Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation. Pharmaceuticals. https://doi.org/10.3390/ph11040097
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.